Search

Find exactly what you’re looking for.

Showing 1-7 of 7 results

Saul Ewing LLP, a full-service national law firm, is proud to announce that Trusts & Estates Practice Co-Chair Jeffrey Glaser was included in The Daily Record’s 2024 Estate and Trust Law Power List. This group is composed of the most influential and respected practitioners in the estate & trust law...

(Baltimore, MD, January 5, 2024) - Saul Ewing LLP today announced that Jeffrey S. Glaser, Partner and Chair of the Firm’s Trusts & Estates Practice Group, has authored the 19th Supplement to the Maryland Estate Planning, Wills and Trusts Library: Forms and Practice Manual . The 19th Supplement was...

Introduction The introduction to the final regulations issued under the Corporate Transparency Act (“CTA”) by the Financial Crimes Enforcement Network of the United States Treasury (“FinCEN”) states that, “[i]llicit actors frequently use corporate structures such as shell and front companies to...

Saul Ewing LLP, a full-service national law firm, today announced that the firm was recognized as Band 1 for Private Wealth Law in Maryland in Chambers High Net Worth 2023. Additionally, Jeff Glaser, chair of the firm's Personal Wealth, Estates & Trusts Practice, was ranked as a Band 1 attorney...

The FTC has announced the annual updates to the Hart-Scott-Rodino (“HSR”) size thresholds, fees and the daily penalty for HSR violations. The updated thresholds and fees were published in the Federal Register on January 26, 2023 and will take effect on February 27, 2023. See Federal Register...

LATEST UPDATE The FTC has voted to extend the public comment period on its proposed rule to ban employers from imposing non-competes on their workers, and will now be accepting comments on the proposed rule until April 19, 2023. Comments can still be submitted in either writing or online using the...

Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...

For More Information